Observational Study
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Feb 16, 2024; 12(5): 951-965
Published online Feb 16, 2024. doi: 10.12998/wjcc.v12.i5.951
Urinary metabolic profiles during Helicobacter pylori eradication in chronic gastritis
Wen-Ting An, Yu-Xia Hao, Hong-Xia Li, Xing-Kang Wu
Wen-Ting An, Department of Pharmacy, Shanxi Provincial People’s Hospital, Taiyuan 030012, Shanxi Province, China
Yu-Xia Hao, Department of Gastroenterology, Shanxi Provincial People's Hospital, Taiyuan 030012, Shanxi Province, China
Hong-Xia Li, Department of Oncology, Shanxi Provincial People’s Hospital, Taiyuan 030012, Shanxi Province, China
Xing-Kang Wu, Modern Research Center for Traditional Chinese Medicine, Shanxi University, Taiyuan 030006, Shanxi Province, China
Co-first authors: Wen-Ting An and Yu-Xia Hao.
Co-corresponding authors: Hong-Xia Li and Xing-Kang Wu.
Author contributions: An WT contributed to conceptualization, investigation, methodology, project administration, resources, data curation, writing and formal analysis; Hao YX contributed to investigation, methodology, data curation and formal analysis; Wu XK contributed to supervision, writing, review and editing; Li HX contributed to conceptualization, methodology, supervision, funding acquisition, review and editing; all authors read and approved the final manuscript.
Supported by Shanxi Provincial Health Commission, No. 2019022.
Institutional review board statement: This study was approved by the Ethics Committee of Shanxi Provincial People’s Hospital (No. 2022-167).
Informed consent statement: All the patients voluntarily participated in the study and signed informed consent forms.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: All data and materials are available from the corresponding author.
STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hong-Xia Li, MMed, Chief Physician, Department of Oncology, Shanxi Provincial People’s Hospital, No. 29 Shuangta Road, Taiyuan 030012, Shanxi Province, China. 345lihongxia@163.com
Received: November 3, 2023
Peer-review started: November 3, 2023
First decision: December 6, 2023
Revised: December 14, 2023
Accepted: January 22, 2024
Article in press: January 22, 2024
Published online: February 16, 2024
ARTICLE HIGHLIGHTS
Research background

Helicobacter pylori (H. pylori) infection is a major risk factor of chronic gastritis, which perhaps influence approximately one-half of global population. H. pylori eradication is a popular treatment method for H. pylori-positive chronic gastritis, but its mechanism is far from clear.

Research motivation

Urinary metabolomics is gradually applied to mine the treatment mechanism of gastric diseases. However, there is no clinical study on urinary metabolomics of chronic gastritis.

Research objectives

This article aimed to investigate metabolic profiles of urine obtained during H. pylori eradication from patients with chronic gastritis.

Research methods

In this article, we applied LC-MS-based metabolomics and network pharmacology to investigate the relationships between urinary metabolites and H. pylori-positive chronic gastritis via a clinical follow-up study.

Research results

Our study revealed the different urinary metabolic profiles of H. pylori-positive chronic gastritis before and after H. pylori eradication. The metabolites regulated by H. pylori eradication include: cis-aconitic acid, isocitric acid, citric acid, L-tyrosine, L-phenylalanine, L-tryptophan and hippuric acid, which were involved in four metabolic pathways: (1) Phenylalanine metabolism; (2) phenylalanine, tyrosine and tryptophan biosynthesis; (3) citrate cycle; and (4) glyoxylate and dicarboxylate metabolism. Integrated metabolomics and network pharmacology revealed that MPO, COMT, TPO, TH, EPX, CMA1, DDC, TPH1 and LPO were the key proteins involved in the involved the biological progress of H. pylori eradication in chronic gastritis.

Research conclusions

Our research provides a new perspective for exploring the clinical significance of urinary metabolites in chronic gastritis.

Research perspectives

Although this is a groundbreaking original clinical study of H. pylori-positive chronic gastritis, it is limited in that the results still require confirmation in further studies, such as targeted metabolomics, larger patient sample size, and animal experimental studies.